PCME is an accredited provider specializing in innovative continuing medical education solutions.
PCME is an accredited provider specializing in innovative continuing medical education solutions.
The importance of the relationship between the kidney and heart in acute decompensated heart failure (ADHF) cannot be overstated, and renal dysfunction is one of the most important comorbidities in heart failure. Decreased glomerular filtration rate is a strong predictor of cardiovascular mortality and complications. Conversely, ADHF can accelerate a worsening of renal function.
ADHF results in about 1 million hospital admissions annually in the United States, and the accompanying prognoses are poor, with 3-4% in-hospital mortality and rates as high as 50% for 60-to-90-day post-discharge mortality and rehospitalization. The triggering event in ADHF involves reduced cardiac output, which activates a number of responses designed to preserve arterial volume and pressure. Compensatory neurohormonal reflexes attempt to preserve circulatory integrity in ADHF, but eventually impose deleterious effects (e.g. pulmonary edema, increased cardiac afterload and preload, excessive renal vasoconstriction, and abnormal sodium and water retention). These responses also set the stage for the development of progressive renal dysfunction and continued volume overload and fluid/electrolyte imbalances. Clearly, heart failure is a multifaceted disorder and, in recent years, an increased understanding of the pathophysiological mechanisms of heart failure has led to an increased scope of therapies available to treat the condition.
This educational program explores the relationship between the kidney and the heart in ADHF by reviewing the most recent data on the clinical consequences of the cardiorenal syndrome, as well as discusses the role of free water clearance and hyponatremia in ADHF and the renal consequences of neurohormonal activation. It features 5 internationally recognized experts in the management of heart failure and includes panel discussions throughout allowing for discussion of challenging clinical scenarios and direct interaction between the faculty and attendees.
 |
Clyde W. Yancy, MD, FACC, FAHA, MACP (Chair) (read bio) Medical Director, Baylor Heart and Vascular Institute Chief, Cardiothoracic Transplantation Baylor University Medical Center Dallas, TX |
 |
Barry M. Massie, MD (read bio) Professor of Medicine University of California, San Francisco Chief, Cardiology Division San Francisco VA Medical Center San Francisco, CA |
 |
James E. Udelson, MD (read bio) Chief, Division of Cardiology Tufts Medical Center Tufts University School of Medicine Boston, MA |
 |
Robert W. Schrier, MD (read bio) Division of Renal Diseases and Hypertension University of Colorado Denver Aurora, CO |
 |
John C. Burnett, Jr., MD (read bio) Marriott Family Professor of Cardiovascular Research Mayo Clinic College of Medicine Rochester, MN |
Researchers, academics, clinicians, and other health care professionals involved in the management of heart failure.
This activity was designed to address the following IOM competencies: provide patient-centered care, and employ evidence-based practice.
Upon completion of this program, attendees will be able to:
The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this educational activity for a maximum of 2 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME, as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. Disclosures will be made known to the participants prior to the activity.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Clyde W. Yancy, MD, FACC, FAHA, MACP (Chair): Nothing to Disclose
Barry M. Massie, MD: Consultant/Advisory Board: Merck, Nile Therapeutics
James E. Udelson, MD: Consultant/Advisory Board: Otsuka America Pharmaceutical, Biogen, Pericor, Bioline
Robert W. Schrier, MD: Researcher: Astellas; Consultant/Advisory Board/Speaker: Otsuka America Pharmaceutical
John C. Burnett, Jr., MD: Researcher: Otsuka America Pharmaceutical; Consultant/Advisory Board: Nile Therapeutics; Speaker: Bayer
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Laurie Frueh, MD; Barry Watkins, PhD; Jay Katz; Bradley Pine; Blair St. Amand; Dana Simpler, MD: Nothing to disclose
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.
| Sponsored by |
This program is supported through an educational grant fromOtsuka America Pharmaceutical, Inc. |
By clicking this button you are agreeing that you have read and understood the CME Statements above.
